Navigation Links
Lumena Pharmaceuticals Launches Global Clinical Program to Evaluate Safety and Efficacy of LUM001 in Children with Alagille Syndrome
Date:9/26/2013

ill be eligible for participation in a long-term extension study.  For more information about the IMAGO study, visit the study page at clinicaltrials.gov, a registry of funded research studies in the United States and around the world. Information about the ITCH study will also be available at clinicaltrials.gov once the study starts in the U.S.

"I think that I can speak on behalf of the Alagille syndrome community when I say that we enthusiastically support Lumena's work to develop safe, oral therapies to treat Alagille syndrome, and I am especially glad that the company is planning an extension study that allows for patients to have long-term access to this treatment while it is in development," said Cindy Hahn, founder and CEO of the Alagille Syndrome Alliance.

About LUM001

LUM001 is an inhibitor of the apical sodium-dependent bile acid transporter (ASBT), which recycles intestinal bile acids back into the circulation. LUM001 has been studied in 12 clinical trials in more than 1,400 subjects. In previous trials, LUM001 was shown to be generally safe, and the most common side effect, gastrointestinal disturbance, was usually mild and transient in nature. Clinical studies have demonstrated that LUM001 can reduce serum bile acid levels. Reductions in bile acids may alleviate symptoms and improve liver function in many patients with cholestatic liver disease.

Lumena plans to initiate Phase II studies of LUM001 in adults with primary biliary cirrhosis (PBC), children with progressive familial intrahepatic cholestasis (PFIC), and in patients with primary sclerosing cholangitis (PSC) in late 2013. Lumena has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA) Office of Orphan Product Development for LUM001<
'/>"/>

SOURCE Lumena Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ampio Pharmaceuticals, Inc. Announces $25 Million Financing
2. KaloBios Pharmaceuticals, Inc. Prices Public Offering of Common Stock
3. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AMAG Pharmaceuticals, Inc. -- AMAG
4. Anthera Pharmaceuticals Announces Emerging Data from Phase 2 Open-Label Extension Study to be Presented at the ACR/ARHP 2013 Annual Scientific Meeting
5. Isis Pharmaceuticals to Present at the Leerink Swann Rare Disease Roundtable
6. Edison Pharmaceuticals Announces Initiation of NIH-Sponsored EPI-743 Clinical Trial with NIH Undiagnosed Diseases Program Patients
7. Inovio Pharmaceuticals Targets Transformation of Monoclonal Antibody Therapies
8. Servier Voluntary Public Offer for all Outstanding Shares of Egis Pharmaceuticals PLC
9. Boehringer Ingelheim Pharmaceuticals, Inc. colabora con Univision Communications Inc. para lanzar una campaña integrada en español
10. Boehringer Ingelheim Pharmaceuticals, Inc. Collaborates With Univision Communications Inc. To Launch An Integrated Campaign In Spanish
11. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015  Bionik Laboratories Corp. (OTC:DWTPD), ... announced today that it acquired Bionik Laboratories, Inc., a ... completed the sale to qualified accredited investors of units ... gross proceeds of approximately $6.2 million. Shares of the ... the OTC Markets under the symbol "DWTPD" until FINRA,s ...
(Date:2/26/2015)... DALLAS , February 27, 2015 ... Review, H2 2014 market research report to its ... the Corneal Ulcers, therapeutic pipeline. The ... information on the therapeutic development for Corneal Ulcers. ... infections that includes bacterial infections, viral infections & ...
(Date:2/26/2015)... MOUNTAIN VIEW, Calif. , Feb. 26, 2015  IRIDEX ... will release its fourth quarter and full year 2014 financial ... 2015.   In conjunction with the release, the Company will ... 5:00 p.m. Eastern Time on Thursday, March 5, ... other business developments. Interested parties may access the ...
Breaking Medicine Technology:Bionik Laboratories Raises $6.2 Million 2Bionik Laboratories Raises $6.2 Million 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 2Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 4Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 5IRIDEX Announces Fourth Quarter and Full Year 2014 Conference Call and Release Date 2
... - Cobalis Corp.,(OTCBB:CLSC), a pharmaceutical development company ... from two Phase III clinical trials for ... moderately severe,seasonal allergic rhinitis, commonly known as ... levels in both placebo and,PreHistin-treated patient groups, ...
... cell lung cancer -, LOS ANGELES, July 09, ... positive Phase III clinical,data published in the July ... that low expression of the biomarker,Excision-Repair Cross-Complementing 1 ... cancer (NSCLC) predicts for,sensitivity to cisplatin-based chemotherapy. ERCC-1 ...
Cached Medicine Technology:Cobalis Reports Phase III Trial Results for PreHistin in Seasonal,Allergic Rhinitis 2Cobalis Reports Phase III Trial Results for PreHistin in Seasonal,Allergic Rhinitis 3Cobalis Reports Phase III Trial Results for PreHistin in Seasonal,Allergic Rhinitis 4Cobalis Reports Phase III Trial Results for PreHistin in Seasonal,Allergic Rhinitis 5Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 2Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 3Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 4
(Date:2/27/2015)... Legislation passed today by the House ... to help prevent inappropriate prescriptions in Medicare Part ... the Integrity of Medicare Act (PIMA), introduced by ... (R-TX) and Ranking Member Jim McDermott (D-WA), recognizes ... epidemic and implement the right policies, said the ...
(Date:2/27/2015)... Dawn Greene Hospice, a 10-bed facility located on the 15th ... East Side, was officially dedicated and blessed at a ceremony ... Cardinal Dolan. , Thomas J. Fahey, Jr., MD, chairman of ... the ArchCare Board of Trustees, presided over the event with ... MMW, and Christina McInerney, president and CEO of The Jerome ...
(Date:2/27/2015)... February 27, 2015 Mediaplanet today announces ... Health,” a campaign that aims to bring blood health ... care conversation. The stories in this edition go beyond ... of clinical care, hard-hitting advocacy, research and technological strides ... According the American Cancer Society, approximately every 3 ...
(Date:2/27/2015)... Healthpointe is now performing arthroscopy ... or diseases affecting the elbow , wrist ... throughout Southern California, and are dedicated in providing ... related to the upper extremities. , Dr. ... board-certified and fully trained in treating an array ...
(Date:2/27/2015)... 27, 2015 Dr. Christopher Saunders, a ... Special at his Chadds Ford, Pa., location. The spring ... 2015, and will be priced at $3,950 with all ... implants, it will include more than $3,000 in MedSpa ... of free Dysport. , Space is very limited, so ...
Breaking Medicine News(10 mins):Health News:PCMA Statement on the ‘Protecting the Integrity of Medicare Act’ 2Health News:The Dawn Greene Hospice Is Officially Dedicated 2Health News:The Dawn Greene Hospice Is Officially Dedicated 3Health News:Know Your Blood: Raising Awareness through Mediaplanet’s “Blood Health” Campaign 2Health News:Healthpointe is Now Performing Arthroscopic Surgery Techniques for Elbow, Hand and Wrist Injuries and Diseases, such as certain Ganglion Cysts 2Health News:Dr. Christopher Saunders Announces Spring Breast Augmentation Special at $3,950 2Health News:Dr. Christopher Saunders Announces Spring Breast Augmentation Special at $3,950 3
... ... Single Sign On Manager to allow complete its Identity Management Suite. Software allows for ... , ... 24, 2010 -- With the release of Enterprise Single Sign On Manager (E-SSO-M), Tools4ever ...
... ... Branding & Website , ... Stafford, VA (PRWeb) February 23, 2010 -- FlexRN, a nurse staffing agency ... and the launch of its new website at www.flexRN.com . The efforts ...
... others , WEDNESDAY, Feb. 24 (HealthDay News) -- ... by the experience, an English study finds. , University ... 270 students, and found little difference between students of ... male students actually had higher productivity following their parents, ...
... ... Mexico from Honeymooners to Business travelers to Spring Break Vacations , ... (PRWEB) -- When in Mexico for spring break, family ... an unforeseen emergency. AssistCare Mexico , a concierge-style health and security service with operations ...
... ... ... , ... , ...
... UK ... magnesium products, including magnesium oil, magnesium gel, and magnesium bath flakes. ... San Ramon, CA ... www.GoodHealthNaturally.com as the exclusive UK distributor of its Ancient Minerals topical magnesium supplements, ...
Cached Medicine News:Health News:Enterprise SSO Manager From Tools4ever Revolutionizes Identity and Access Management 2Health News:Nurse Staffing Agency, FlexRN, Unveils New Corporate Branding & Website 2Health News:Just in Time for Spring Break 2010, AssistCard Mexico Launches Concierge-style Health and Security Services for Travelers to Mexico 2Health News:Just in Time for Spring Break 2010, AssistCard Mexico Launches Concierge-style Health and Security Services for Travelers to Mexico 3Health News:Just in Time for Spring Break 2010, AssistCard Mexico Launches Concierge-style Health and Security Services for Travelers to Mexico 4Health News:Northern Illinois Proton Center on the Verge of Major Medical Breakthrough 2Health News:Northern Illinois Proton Center on the Verge of Major Medical Breakthrough 3Health News:Northern Illinois Proton Center on the Verge of Major Medical Breakthrough 4Health News:Northern Illinois Proton Center on the Verge of Major Medical Breakthrough 5Health News:Northern Illinois Proton Center on the Verge of Major Medical Breakthrough 6Health News:Northern Illinois Proton Center on the Verge of Major Medical Breakthrough 7Health News:Northern Illinois Proton Center on the Verge of Major Medical Breakthrough 8Health News:Ancient Minerals Topical Magnesium Oil Now Available in the UK 2Health News:Ancient Minerals Topical Magnesium Oil Now Available in the UK 3
Quick Release buckle apron is user friendly with large support straps crisscrossing the back allowing proper placement of the belt at your waist....
... Our unique velcro design ... for additional support and comfort. ... two velcro flaps aid in ... A comfortable fit is attained ...
This one of a kind design also provides full body protection. Split down each side, like a poncho, this apron is simple to put on and take off. Available with an orthopedic wide belt or buckle belt....
Gonad shields protect the reproductive organs. Available in male and female models. One size fits all....
Medicine Products: